HH-2853 is under clinical development by Shanghai Haihe Biopharma and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase II drugs for Soft Tissue Sarcoma have a 26% phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback